| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
George Massaro last filed a Form 4 in May 2025, as Director at HURN. The filings on record cover 2 companies. George Massaro's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns George Massaro a middling insider score of 66/100, based on 8 past trades. Over a 12-month horizon, 83.3% of those trades were profitable, with an average 12-month return of +25.7%.
At the last filing, the largest reported position was 17,719 shares of HURN. The HURN filings lean toward selling, a net 16,838 shares.
George Massaro has 61 Form 4 filings on record from January 2015 to May 2025, across 2 companies: Director at Charles River Laboratories International (CRL), 2015–2025; Director at Huron Consulting Group (HURN), 2015–2020.
The 278 reported transactions were 245 open-market sales, 15 stock awards, 6 option or other derivative awards and 6 gifts, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 47 sales worth about $6.9M.
The largest open-market sale was 3,370 shares of CRL at an average $336.96 on May 6, 2021, about $1.1M. Twelve months later CRL was down 28%.
All 4 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
Shares as reported in the last Form 4 for each company; the most recent is from May 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 15, 2025 | CRL Charles River Laboratories International, Inc. | Director | Sell10b5-1 | 140 | $137.57 | $19,260.48 | -2.4% | +11.6% | - | |
| May 14, 2025 | CRL Charles River Laboratories International, Inc. | Director | Sell10b5-1 | 140 | $140.74 | $19,702.90 | -2.4% | +9.9% | - | |
| May 15, 2024 | CRL Charles River Laboratories International, Inc. | Director | Sell10b5-1 | 332 | $235.62 | $78,225.37 | -5.4% | -12.5% | -40.3% | |
| May 11, 2023 | CRL Charles River Laboratories International, Inc. | Director | Sell10b5-1 | 288 | $193.43 | $55,707.84 | -5.5% | +10.2% | +16.5% | |
| May 9, 2022 | CRL Charles River Laboratories International, Inc. | Director | Sell | 178 | $230.96 | $41,110.18 | -3.7% | -3.6% | -18.1% | |
| Aug 31, 2021 | CRL Charles River Laboratories International, Inc. | Director | Sale+OE | 2,539 | $442.48 | $1,123,457.21 | -34.3% | -15.4% | -53.8% | |
| May 11, 2021 | CRL Charles River Laboratories International, Inc. | Director | Sell | 371 | $320.06 | $118,742.73 | -6.5% | +27.7% | -30.6% | |
| May 6, 2021 | CRL Charles River Laboratories International, Inc. | Director | Sell | 3,370 | $336.96 | $1,135,560.77 | -38.6% | +23.6% | -28.2% | |
| Sep 14, 2020 | CRL Charles River Laboratories International, Inc. | Director | Sell | 1,943 | $219.91 | $427,283.57 | -17.1% | - | - | |
| May 22, 2020 | CRL Charles River Laboratories International, Inc. | Director | Sell | 941 | $173.40 | $163,168.18 | -7.3% | - | - |